| Literature DB >> 35677154 |
Xinlin He1,2, Zhengyu Li1,2.
Abstract
Background: Debulking cytoreduction surgery with bowel resection is a common intervention for ovarian cancer. It is controversial whether ostomy causes worse survival outcomes and how clinical physicians should choose which patients to undergo ostomy. During this study, we performed a systematic review to determine whether ostomy leads to worse outcomes after bowel resection compared to anastomosis. We also summarized the possible indications for ostomy.Entities:
Keywords: bowel resection; meta-analysis; ostomy; ovarian cancer; systematic review
Year: 2022 PMID: 35677154 PMCID: PMC9169036 DOI: 10.3389/fonc.2022.892376
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1PRISMA diagram.
Information collected from the three studies.
| Canlorbe et al. | Fleetwood et al. | Lago et al. | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary anastomosis | Ostomy | Primary anastomosis | Ostomy | Primary anastomosis / Ghost ileostomy | Ostomy | ||||||
|
| |||||||||||
| Age (mean) | 53 | 53 | 60.1 (overall) | 55.7 / 54.5 | 60.9 | ||||||
| BMI (mean) | 24 | 23 | Not reported | 25.1 / 24.8 | 25.1 | ||||||
| ASA score | |||||||||||
| 1 | 7.8% | 0 | Not reported | 81.9% / 92.9% (combined scores 1 and 2) | 63.2% (combined scores 1 and 2) | ||||||
| 2 | 67.8% | 55.6% | |||||||||
| 3 | 18.9% | 44.4% | |||||||||
| Unknown | 5.6% | 0 | |||||||||
| Comorbidities | 86.3% | 85.9% | |||||||||
| Hypertension | 18.9% | 3.3% | 41.4% | 40.6% | Not reported | ||||||
| Diabetes | 12.2% | 11.1% | Not reported | 2.8% / 2.4% | 10.5% | ||||||
| Corticoid/steroid use | 1.1% | 0 | 3.1% | 3.6% | 2.8% / 7.1% | 0 | |||||
| FIGO stage | |||||||||||
| Not applicable (relapse) | Not reported | 8.3% / 9.5% | 10.5% | ||||||||
| II | 6.9% / 9.5% | 0 | |||||||||
| III | 92.2% | 100% | 59.7% / 61.9% | 84.2% | |||||||
| IV | 7.8% | 0 | 25.0% / 19.0% | 15.8% | |||||||
| Preoperative serum results | |||||||||||
| CA125 (>500 U/mL) | 35.6% | 22.2% | Not reported | Not reported | |||||||
| Hyperalbuminemia (<3.5 g/dL) | Not reported | 25.0% / 23.8% | 10.5% | ||||||||
| Mean albumin level (g/dl) | 3.73 | 3.58 | |||||||||
| Compared the baseline data between groups | Yes | Yes | Yes | ||||||||
|
| |||||||||||
| Mean operative time (min) | 466 | 557 | Not reported | 363 / 360 | 402 | ||||||
| Intraoperative transfusion | Not reported | 61.1% / 42.9% | 78.9% | ||||||||
| Mean intraoperative blood loss (mL) | 1508 | 1100 | 446 / 557 | 683 | |||||||
| Repeat bowel resection | 32.2% | 66.7% | 18.1% / 14.3% | 31.6% | |||||||
| Additional surgery | |||||||||||
| Lymphadenectomy | 85.6% | 66.7% | 55.6% / 69.0% | 47.4% | |||||||
| Omentectomy | Not reported | 90.3% / 88.1% | 84.2% | ||||||||
| Low anastomosis from the anal verge (<5 cm) | Not reported | 6.9% / 14.3% | 5.3% | ||||||||
| Compared the surgery information | Yes | No | Yes | ||||||||
|
| |||||||||||
| Mean hospital stay (day) | 18 | 20 | Not reported | 10 (ghost ileostomy) | 11 | ||||||
| Adverse events (grade III or higher) | 27.8% | 22.2% | 36.5% | 36.9% | |||||||
| Stoma-related adverse event | 7.1% (ghost ileostomy) | 78.9% | |||||||||
| AL rate | 6.7%(in Grade III) | 11.1%(in Grade III) | Not reported | 5.6% / 4.8% | 5.3% | ||||||
| Reverse rate | 88.9% | Not reported | 73.7% | ||||||||
| Median overall survival | 31 months | Not reported | |||||||||
| Progression-free survival | 17 months | ||||||||||
| 30-day morbidity | Ostomy status: OR, 1.97 (univariate) | ||||||||||
AL, anastomotic leakage; ASA, American Society of Anesthesiology; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; OR, odds ratio.